miR‑149‑5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway

Manman Xu, Juan Xiao, Ming Chen, Linjing Yuan, Jundong Li, Hongwei Shen, Shuzhong YaoInternational Journal of Oncology 2018 · DOI

Abstract

Chemotherapeutic resistance remains a critical clinical issue and is responsible for treatment failure in patients with ovarian cancer. Evidence of the involvement of miRNAs in chemoresistance in ovarian cancer has been recently emerging. However, the underlying molecular links between chemoresistance and miRNAs remain largely unknown. In this study, we report that miR‑149‑5p expression is markedly elevated in chemoresistant ovarian cancer tissues compared with the chemosensitive ovarian cancer tissues. Furthermore, the silencing of miR‑149‑5p enhanced the chemosensitivity of ovarian cancer cells to cisplatin in vitro and in vivo. Conversely, the upregulation of miR‑149‑5p aggravated chemoresistance in ovarian cancer cells. Our results further revealed that miR‑149‑5p directly targeted the core kinase components of the Hippo signaling pathway, STE20-like kinase (MST)1 and protein salvador homolog 1 (SAV1), resulting in the inactivation of TEA domain (TEAD) transcription. On the whole, our findings reveal a novel mechanism of action of miR‑149‑5p in inducing chemotherapeutic resistance in ovarian cancer, indicating that miR‑149‑5p may serve as a chemotherapeutic response indicator and a potential therapeutic target in ovarian cancer.

Introduction

Ovarian cancer is the fifth leading cause of cancer-related deaths in women, largely due to the frequent development of resistance to standard platinum-based treatments like cisplatin. While microRNAs (miRNAs)—small non-coding RNAs that regulate gene expression—are known to influence chemoresistance, the specific molecular pathways involved have remained poorly defined. This study investigates whether miR-149-5p acts as a key driver of resistance and identifies the signaling mechanisms it hijacks to promote tumor survival.

Methods and Datasets

The researchers employed a multi-pronged approach combining clinical data, molecular biology, and animal models:

  • Clinical Profiling: miR-149-5p levels were compared in chemoresistant vs. chemosensitive tissues using The Cancer Genome Atlas (TCGA) dataset (n=382) and a local cohort of 20 patients from Sun Yat-sen University Cancer Center.
  • Functional and Target Assays: Gain-of-function and loss-of-function experiments were conducted across seven human ovarian cancer cell lines. Luciferase reporter assays and RNA immunoprecipitation (RIP) were used to confirm direct miRNA-target interactions.
  • In Vivo Models: Mouse xenograft models were established to evaluate the therapeutic potential of silencing miR-149-5p in combination with cisplatin.

Key Results

Clinical Correlation and Biomarker Potential

Analysis of both large-scale genomic data and local clinical samples demonstrated that miR-149-5p expression is significantly higher in chemoresistant tissues compared to sensitive ones ($p < 0.001$). Furthermore, expression levels correlated with clinical response categories, suggesting its potential as a diagnostic marker for predicting chemotherapy failure.

Figure 1: miR-149-5p expression levels across clinical cohorts and cell lines. (A) TCGA data comparing sensitive vs. resistant patients. (B) Expression correlation with clinical response. (C) Comparison between benign lesions and tumor tissues. (D) Expression profiles in sensitive vs. resistant ovarian cancer cell lines.

Mechanism: Hijacking the Hippo Pathway

The study revealed that miR-149-5p promotes resistance by effectively "cutting the brakes" on the Hippo signaling pathway, a critical tumor suppressor system.

  • Dual Targeting: miR-149-5p directly binds to and suppresses the 3'UTR of both MST1 and SAV1, core kinase components of the Hippo pathway.
  • Nuclear Translocation: Suppression of these kinases prevents the degradation of oncogenic YAP and TAZ proteins. These proteins then translocate to the nucleus to activate TEAD transcription factors, which drive the expression of genes associated with cell survival and drug evasion.

Reversing Resistance

Silencing miR-149-5p in resistant cell lines (e.g., HO-8910 and SK-OV-3) significantly increased their sensitivity to cisplatin, leading to higher rates of apoptosis. In animal models, the combination of cisplatin and miR-149-5p silencing resulted in the most significant reduction in tumor volume and improved survival outcomes compared to chemotherapy alone.

Discussion and Limitations

While miR-149-5p presents a promising therapeutic target, several challenges remain. Delivering miRNA inhibitors (anti-miRs) effectively to human tumors is a major pharmacological hurdle. Additionally, while this study clarifies the downstream effects of miR-149-5p, the upstream regulators causing its overexpression in resistant tumors remain unknown. Future research with larger multi-center cohorts is necessary to validate miR-149-5p as a definitive clinical biomarker.

Summary updated

Abstract

Chemotherapeutic resistance remains a critical clinical issue is responsible for treatment failure in patients with ovarian cancer. Evidence of the involvement of miRNAs in chemoresistance in ovarian cancer has been recently emerging. However, the underlying molecular links between chemoresistance and miRNAs remain largely unknown. In this study, we report that miR‑149‑5p expression is markedly elevated in chemoresistant ovarian cancer tissues compared with the chemosensitive ovarian cancer tissues. Furthermore, the silencing of miR‑149‑5p enhanced the chemosensitivity of ovarian cancer cells to cisplatin in vitro and in vivo. Conversely, the upregulation of miR‑149‑5p aggravated chemoresistance in ovarian cancer cells. Our results further revealed that miR‑149‑5p directly targeted the core kinase components of the Hippo signaling pathway, STE20-like kinase (MST)1 and protein salvador homolog 1 (SAV1), resulting in the inactivation of TEA domain (TEAD) transcription. On the whole, our findings reveal a novel mechanism of of action miR‑149‑5p in inducing chemotherapeutic resistance in ovarian cancer, indicating that miR‑149‑5p may serve as a chemotherapeutic response indicator and a potential therapeutic target in ovarian cancer.
BibTeX
@article{xu2018mir,
  author = {Manman Xu and Juan Xiao and Ming Chen and Linjing Yuan and Jundong Li and Hongwei Shen and Shuzhong Yao},
  title = {{miR‑149‑5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway}},
  journal = {International Journal of Oncology},
  year = {2018},
  doi = {10.3892/ijo.2018.4252},
}
Figure